PURPOSE: We prospectively examined the development of depressive symptoms and fatigue among men with locally advanced prostate cancer receiving hormone therapy. METHODS:Fifty-two men with advanced or recurrent prostate cancer were randomly assigned to receive either parenteral leuprolide or oral bicalutamide. Patients completed the Beck Depression Inventory (BDI) and Fatigue Severity Scale (FSS) at pretreatment baseline, 6 months, and 12 months. RESULTS:Rates of at least mild depression ranged from 10.4 to 16.3% over the 12 months and were not significantly different at each time point. Mean change in BDI scores from baseline to 6 months for the entire sample was 0.91 (SE = 0.73), and from baseline to 12 months was 0.35 (SE = 0.67). Mean FSS scores increased significantly from baseline (M = 24.43, SD = 11.75) to 6 months (M = 27.93, SD = 13.52) and remained steady at 12 months (M = 27.80, SD = 14.44). There were no significant differences in depression between the two types of hormone therapy. CONCLUSION:Hormone therapy does not appear to cause clinically significant changes in depression among men with locally advanced prostate cancer. However, fatigue increased significantly over the study period.
RCT Entities:
PURPOSE: We prospectively examined the development of depressive symptoms and fatigue among men with locally advanced prostate cancer receiving hormone therapy. METHODS: Fifty-two men with advanced or recurrent prostate cancer were randomly assigned to receive either parenteral leuprolide or oral bicalutamide. Patients completed the Beck Depression Inventory (BDI) and Fatigue Severity Scale (FSS) at pretreatment baseline, 6 months, and 12 months. RESULTS: Rates of at least mild depression ranged from 10.4 to 16.3% over the 12 months and were not significantly different at each time point. Mean change in BDI scores from baseline to 6 months for the entire sample was 0.91 (SE = 0.73), and from baseline to 12 months was 0.35 (SE = 0.67). Mean FSS scores increased significantly from baseline (M = 24.43, SD = 11.75) to 6 months (M = 27.93, SD = 13.52) and remained steady at 12 months (M = 27.80, SD = 14.44). There were no significant differences in depression between the two types of hormone therapy. CONCLUSION: Hormone therapy does not appear to cause clinically significant changes in depression among men with locally advanced prostate cancer. However, fatigue increased significantly over the study period.
Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang Journal: Oncologist Date: 2000
Authors: Peter J Schmidt; Kate L Berlin; Merry A Danaceau; Amy Neeren; Nazli A Haq; Catherine A Roca; David R Rubinow Journal: Arch Gen Psychiatry Date: 2004-10
Authors: Matthew R Smith; Melissa Goode; Anthony L Zietman; Francis J McGovern; Hang Lee; Joel S Finkelstein Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Morgan Lee; Heather S Jim; Mayer Fishman; Babu Zachariah; Randy Heysek; Matthew Biagioli; Paul B Jacobsen Journal: Psychooncology Date: 2014-06-13 Impact factor: 3.894
Authors: Charles Kamen; Karen M Mustian; Charles Heckler; Michelle C Janelsins; Luke J Peppone; Supriya Mohile; James M McMahon; Raymond Lord; Patrick J Flynn; Matthias Weiss; David Spiegel; Gary R Morrow Journal: J Cancer Surviv Date: 2015-01-21 Impact factor: 4.442
Authors: Linda F Brown; Kevin L Rand; Silvia M Bigatti; Jesse C Stewart; Dale E Theobald; Jingwei Wu; Kurt Kroenke Journal: Health Psychol Date: 2012-08-27 Impact factor: 4.267
Authors: Ashley M Nelson; Brian D Gonzalez; Heather S L Jim; Julie M Cessna; Steven K Sutton; Brent J Small; Mayer N Fishman; Babu Zachariah; Paul B Jacobsen Journal: Support Care Cancer Date: 2016-05-03 Impact factor: 3.603
Authors: Aasha I Hoogland; Heather S L Jim; Brian D Gonzalez; Brent J Small; Danielle Gilvary; Elizabeth C Breen; Julienne E Bower; Mayer Fishman; Babu Zachariah; Paul B Jacobsen Journal: Cancer Date: 2020-12-30 Impact factor: 6.860
Authors: Christopher M Celano; Oliver Freudenreich; Carlos Fernandez-Robles; Theodore A Stern; Mario A Caro; Jeff C Huffman Journal: Dialogues Clin Neurosci Date: 2011 Impact factor: 5.986
Authors: Kathryn T Dinh; Gally Reznor; Vinayak Muralidhar; Brandon A Mahal; Michelle D Nezolosky; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Christopher J Sweeney; Quoc-Dien Trinh; Paul L Nguyen Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 50.717